% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Barba:266099,
      author       = {Barba, Lorenzo and Vollmuth, Christoph and Abu-Rumeileh,
                      Samir and Halbgebauer, Steffen and Oeckl, Patrick and
                      Steinacker, Petra and Kollikowski, Alexander M and Schultz,
                      Cara and Wolf, Judith and Pham, Mirko and Schuhmann, Michael
                      K and Heuschmann, Peter U and Haeusler, Karl Georg and
                      Stoll, Guido and Neugebauer, Hermann and Otto, Markus},
      title        = {{S}erum β-synuclein, neurofilament light chain and glial
                      fibrillary acidic protein as prognostic biomarkers in
                      moderate-to-severe acute ischemic stroke.},
      journal      = {Scientific reports},
      volume       = {13},
      number       = {1},
      issn         = {2045-2322},
      address      = {[London]},
      publisher    = {Macmillan Publishers Limited, part of Springer Nature},
      reportid     = {DZNE-2023-01100},
      pages        = {20941},
      year         = {2023},
      abstract     = {We aimed to assess the prognostic value of serum
                      β-synuclein (β-syn), neurofilament light chain (NfL) and
                      glial fibrillary acidic protein (GFAP) in patients with
                      moderate-to-severe acute ischemic stroke. We measured
                      β-syn, GFAP and NfL in serum samples collected one day
                      after admission in 30 adult patients with moderate-to-severe
                      ischemic stroke due to middle cerebral artery (MCA)
                      occlusion. We tested the associations between biomarker
                      levels and clinical and radiological scores (National
                      Institute of Health Stroke Scale scores, NIHSS, and Alberta
                      Stroke Program Early CT Score, ASPECTS), as well as measures
                      of functional outcome (modified Rankin Scale, mRS). Serum
                      biomarkers were significantly associated with ASPECTS values
                      (β-syn p = 0.0011, GFAP p = 0.0002) but not with NIHSS
                      scores at admission. Patients who received mechanical
                      thrombectomy and intravenous thrombolysis showed lower
                      β-syn (p = 0.029) und NfL concentrations (p = 0.0024)
                      compared to patients who received only mechanical
                      thrombectomy. According to median biomarker levels, patients
                      with high β-syn, NfL or GFAP levels showed, after therapy,
                      lower clinical improvement (i.e., lower 24-h NIHSS change),
                      higher NIHSS scores during hospitalization and higher mRS
                      scores at 3-month follow-up. Elevated serum concentrations
                      of β-syn (p = 0.016), NfL (p = 0.020) or GFAP (p = 0.010)
                      were significantly associated with 3-month mRS of 3-6 vs.
                      0-2 even after accounting for age, sex and renal function.
                      In patients with moderate-to-severe acute ischemic stroke,
                      serum β-syn, NfL and GFAP levels associated with clinical
                      and radiological scores at different timepoints and were
                      able to predict short- and middle-term clinical outcomes.},
      keywords     = {Adult / Humans / beta-Synuclein / Biomarkers / Glial
                      Fibrillary Acidic Protein / Infarction, Middle Cerebral
                      Artery / Intermediate Filaments / Ischemic Stroke /
                      Neurofilament Proteins / Prognosis / Stroke: therapy /
                      beta-Synuclein (NLM Chemicals) / Biomarkers (NLM Chemicals)
                      / Glial Fibrillary Acidic Protein (NLM Chemicals) /
                      Neurofilament Proteins (NLM Chemicals) / GFAP protein, human
                      (NLM Chemicals) / SNCB protein, human (NLM Chemicals)},
      cin          = {AG Öckl},
      ddc          = {600},
      cid          = {I:(DE-2719)5000073},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC10684607},
      pubmed       = {pmid:38017278},
      doi          = {10.1038/s41598-023-47765-7},
      url          = {https://pub.dzne.de/record/266099},
}